Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth.

Salomon LJ, Alfirevic Z, Da Silva Costa F, Deter RL, Figueras F, Ghi T, Glanc P, Khalil A, Lee W, Napolitano R, Papageorghiou A, Sotiriadis A, Stirnemann J, Toi A, Yeo G.

Ultrasound Obstet Gynecol. 2019 Jun;53(6):715-723. doi: 10.1002/uog.20272.

2.

Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer.

Goldberg H, Ramiz AH, Glicksman R, Salgado NS, Chandrasekar T, Klaassen Z, Wallis CJD, Hosni A, Moraes FY, Ghai S, Kulkarni GS, Hamilton RJ, Perlis N, Toi A, Chung P, Evans A, van der Kwast T, Finelli A, Fleshner N, Berlin A.

Eur Urol Oncol. 2019 Feb;2(1):88-96. doi: 10.1016/j.euo.2018.05.003. Epub 2018 May 27.

PMID:
30929849
3.

Fetal myelomeningocele surgery: Only treating the tip of the iceberg.

AlRefai A, Drake J, Kulkarni AV, Connor KL, Shannon P, Toi A, Chitayat D, Blaser S, Church PT, Abbasi N, Ryan G, Van Mieghem T.

Prenat Diagn. 2019 Jan;39(1):10-15. doi: 10.1002/pd.5390. Epub 2018 Dec 10.

PMID:
30536580
4.

Correlation of 3T multiparametric prostate MRI using prostate imaging reporting and data system (PIRADS) version 2 with biopsy as reference standard.

Mathur S, O'Malley ME, Ghai S, Jhaveri K, Sreeharsha B, Margolis M, Zhong L, Maan H, Toi A.

Abdom Radiol (NY). 2019 Jan;44(1):252-258. doi: 10.1007/s00261-018-1696-8.

PMID:
30032385
5.

Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.

Goldberg H, Klaassen Z, Chandrasekar T, Wallis CJD, Toi A, Sayyid R, Bhindi B, Nesbitt M, Evans A, van der Kwast T, Sweet J, Perlis N, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta A, Fleshner N.

J Urol. 2018 Nov;200(5):1056-1061. doi: 10.1016/j.juro.2018.05.017. Epub 2018 Jul 27.

PMID:
29758220
6.

Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.

Prendeville S, Gertner M, Maganti M, Pintilie M, Perlis N, Toi A, Evans AJ, Finelli A, van der Kwast TH, Ghai S.

J Urol. 2018 Jul;200(1):104-113. doi: 10.1016/j.juro.2018.01.081. Epub 2018 Feb 2.

PMID:
29408568
7.

Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.

Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.

Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.

PMID:
28781111
8.

Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Bhindi A, Bhindi B, Kulkarni GS, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Zlotta AR, Finelli A, Fleshner NE.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):41-46. doi: 10.5489/cuaj.4031.

9.

Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.

PMID:
28376164
10.

Psychosocial determinants for treatment decisions in familial retinoblastoma.

Soliman SE, Ulster A, MacDonald H, VandenHoven C, Toi A, Hèon E, Gallie B.

Ophthalmic Genet. 2017 Jul-Aug;38(4):392-394. doi: 10.1080/13816810.2016.1227458. Epub 2017 Jan 13. No abstract available.

PMID:
28085520
11.

Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.

Sayyid R, Perlis N, Ahmad A, Evans A, Toi A, Horrigan M, Finelli A, Zlotta A, Kulkarni G, Hamilton R, Morash C, Fleshner N.

BJU Int. 2017 Jul;120(1):76-82. doi: 10.1111/bju.13733. Epub 2017 Jan 6.

12.

Congenital limb deficiencies with vascular etiology: Possible association with maternal thrombophilia.

Ordal L, Keunen J, Martin N, Shehata N, Borschel GH, Clarke HM, Toi A, Shuman C, Chitayat D.

Am J Med Genet A. 2016 Dec;170(12):3083-3089. doi: 10.1002/ajmg.a.37890. Epub 2016 Aug 17.

PMID:
27530094
13.

Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.

Perlis N, Sayyid R, Evans A, Van Der Kwast T, Toi A, Finelli A, Kulkarni G, Hamilton R, Zlotta AR, Trachtenberg J, Ghai S, Fleshner NE.

J Urol. 2017 Jan;197(1):75-83. doi: 10.1016/j.juro.2016.07.076. Epub 2016 Jul 22.

PMID:
27457260
14.

The pathology of incipient polymicrogyria.

Diamandis P, Chitayat D, Toi A, Blaser S, Shannon P.

Brain Dev. 2017 Jan;39(1):23-39. doi: 10.1016/j.braindev.2016.06.005. Epub 2016 Jul 9.

PMID:
27406708
15.

The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition.

Praissman JL, Willer T, Sheikh MO, Toi A, Chitayat D, Lin YY, Lee H, Stalnaker SH, Wang S, Prabhakar PK, Nelson SF, Stemple DL, Moore SA, Moremen KW, Campbell KP, Wells L.

Elife. 2016 Apr 29;5. pii: e14473. doi: 10.7554/eLife.14473.

16.

Choice of Formula and Accuracy of Fetal Weight Estimation in Small-for-Gestational-Age Fetuses.

Melamed N, Ryan G, Windrim R, Toi A, Kingdom J.

J Ultrasound Med. 2016 Jan;35(1):71-82. doi: 10.7863/ultra.15.02058. Epub 2015 Dec 3.

PMID:
26635253
17.

Maternal Cardiac Output and Fetal Doppler Predict Adverse Neonatal Outcomes in Pregnant Women With Heart Disease.

Wald RM, Silversides CK, Kingdom J, Toi A, Lau CS, Mason J, Colman JM, Sermer M, Siu SC.

J Am Heart Assoc. 2015 Nov 23;4(11). pii: e002414. doi: 10.1161/JAHA.115.002414.

18.

An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.

Komisarenko M, Wong LM, Richard PO, Timilshina N, Toi A, Evans A, Zlotta A, Kulkarni G, Hamilton R, Fleshner N, Finelli A.

J Urol. 2016 Feb;195(2):307-12. doi: 10.1016/j.juro.2015.09.081. Epub 2015 Sep 28.

PMID:
26417646
19.

Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights.

Edwan GA, Ghai S, Margel D, Kulkarni G, Hamilton R, Toi A, Haidar MA, Finelli A, Fleshner NE.

Can Urol Assoc J. 2015 May-Jun;9(5-6):E267-72. doi: 10.5489/cuaj.2562.

20.

[Development of simple processing for deleting undershooting artifact using the FBP method ─evaluation of simulation data─].

Kita A, Onoguchi M, Sugimoto K, Tsuchida T, Toi A, Kishimoto T, Shimada M, Adachi T.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2015 Mar;71(3):201-7. doi: 10.6009/jjrt.2015_JSRT_71.3.201. Japanese.

21.

Infectious complications following transrectal ultrasound-guided prostate biopsy: a Canadian tertiary cancer center experience.

Al-Busaidi I, Leis JA, Gold WL, McGeer A, Toi A.

Infect Control Hosp Epidemiol. 2015 May;36(5):614-6. doi: 10.1017/ice.2015.30. Epub 2015 Feb 23. No abstract available.

PMID:
25703214
22.

Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.

Wong LM, Ferrara S, Alibhai SM, Evans A, Van der Kwast T, Trottier G, Timilshina N, Toi A, Kulkarni G, Hamilton R, Zlotta A, Fleshner N, Finelli A.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):69-74. doi: 10.1038/pcan.2014.48. Epub 2014 Dec 9.

PMID:
25487136
23.

Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

Bhindi B, Mamdani M, Kulkarni GS, Finelli A, Hamilton RJ, Trachtenberg J, Zlotta AR, Evans A, van der Kwast TH, Toi A, Fleshner NE.

J Urol. 2015 May;193(5):1519-24. doi: 10.1016/j.juro.2014.11.096. Epub 2014 Dec 3.

PMID:
25481037
24.

The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy.

Bhindi B, Margel D, Hamilton RJ, Fernandes KA, Trottier G, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Kulkarni GS, Toi A, Evans A, van der Kwast TH, Fleshner NE.

Urology. 2014 Nov;84(5):1073-80. doi: 10.1016/j.urology.2014.05.071. Epub 2014 Oct 24.

PMID:
25443907
25.

Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro.

Yamasaki A, Kasai A, Toi A, Kurita M, Kimoto S, Hayata-Takano A, Nakazawa T, Nagayasu K, Shintani N, Hashimoto R, Ito A, Meltzer HY, Ago Y, Waschek JA, Onaka Y, Matsuda T, Baba A, Hashimoto H.

J Neurochem. 2015 Feb;132(4):418-28. doi: 10.1111/jnc.12999. Epub 2015 Jan 23.

26.

Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy.

Satkunasivam R, Zhang W, Trachtenberg J, Toi A, Yu C, Diamandis E, Kattan MW, Narod SA, Nam RK.

Springerplus. 2014 Jun 11;3:295. doi: 10.1186/2193-1801-3-295. eCollection 2014.

27.

Cerebellar vermis area versus perimeter.

Toi A.

J Matern Fetal Neonatal Med. 2015;28(14):1740. doi: 10.3109/14767058.2014.967675. Epub 2014 Oct 10. No abstract available.

PMID:
25241769
28.

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

Akbari MR, Wallis CJ, Toi A, Trachtenberg J, Sun P, Narod SA, Nam RK.

Br J Cancer. 2014 Sep 9;111(6):1238-40. doi: 10.1038/bjc.2014.428. Epub 2014 Aug 7.

29.

Prospective study of intracranial translucency and the posterior brain in normal fetuses at the 11- to 13-week scan.

Fong KW, Dengler J, Toi A, Menezes RJ, Karimzad Y, Okun N.

J Ultrasound Med. 2014 Aug;33(8):1373-9. doi: 10.7863/ultra.33.8.1373.

PMID:
25063402
30.

Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.

Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Hersey K, Jewett MA, Zlotta AR, Trachtenberg J, Fleshner NE.

Eur Urol. 2014 Nov;66(5):841-8. doi: 10.1016/j.eururo.2014.06.005. Epub 2014 Jun 18.

PMID:
24954793
31.

Development of anti-adhesive spongy sheet composed of hyaluronic acid and collagen containing epidermal growth factor.

Kuroyanagi M, Yamamoto A, Shimizu N, Toi A, Inomata T, Takeda A, Kuroyanagi Y.

J Biomater Sci Polym Ed. 2014;25(12):1253-65. doi: 10.1080/09205063.2014.926579. Epub 2014 Jun 18.

PMID:
24938709
32.

Fetal skeletal dysplasias in a tertiary care center: radiology, pathology, and molecular analysis of 112 cases.

Barkova E, Mohan U, Chitayat D, Keating S, Toi A, Frank J, Frank R, Tomlinson G, Glanc P.

Clin Genet. 2015 Apr;87(4):330-7. doi: 10.1111/cge.12434. Epub 2014 Jul 26.

PMID:
24863959
33.

Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.

Wong LM, Toi A, Van der Kwast T, Trottier G, Alibhai SM, Timilshina N, Evans A, Zlotta A, Fleshner N, Finelli A.

J Urol. 2014 Oct;192(4):1088-93. doi: 10.1016/j.juro.2014.04.010. Epub 2014 Apr 15.

PMID:
24742593
34.

Temporal lobe dysplasia: a characteristic sonographic finding in thanatophoric dysplasia.

Wang DC, Shannon P, Toi A, Chitayat D, Mohan U, Barkova E, Keating S, Tomlinson G, Glanc P.

Ultrasound Obstet Gynecol. 2014 Nov;44(5):588-94. doi: 10.1002/uog.13337. Epub 2014 Oct 13.

35.

Beals syndrome (congenital contractural arachnodactyly): prenatal ultrasound findings and molecular analysis.

Inbar-Feigenberg M, Meirowitz N, Nanda D, Toi A, Okun N, Chitayat D.

Ultrasound Obstet Gynecol. 2014 Oct;44(4):486-90. doi: 10.1002/uog.13350. Epub 2014 Sep 8.

36.

Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.

Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE.

Eur Urol. 2015 Jan;67(1):64-70. doi: 10.1016/j.eururo.2014.01.040. Epub 2014 Feb 14.

PMID:
24568896
37.

[Comparison of the absorbed dose at calibration depth of photon beams using the Japan Society of Medical Physics 12 beam quality conversion factor in the presence or absence of a waterproofing sleeve].

Kinoshita N, Takemura A, Kita A, Murai E, Nishimoto Y, Toi A, Shimada M, Sasamoto K, Adachi T.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2013 Oct;69(10):1161-4. Japanese.

38.

Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort.

Bhindi B, Margel D, Trottier G, Hamilton RJ, Kulkarni GS, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Toi A, Evans A, van der Kwast T, Fleshner NE.

Urology. 2014 Jan;83(1):81-7. doi: 10.1016/j.urology.2013.07.039. Epub 2013 Sep 14.

PMID:
24044911
39.

Dyssegmental dysplasia, Silverman-Handmaker type: prenatal ultrasound findings and molecular analysis.

Ladhani NN, Chitayat D, Nezarati MM, Laureane MC, Keating S, Silver RJ, Unger S, Velsher L, Sirkin W, Toi A, Glanc P.

Prenat Diagn. 2013 Nov;33(11):1039-43. doi: 10.1002/pd.4193. Epub 2013 Aug 4.

PMID:
23836246
40.

Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates?

Wong LM, Trottier G, Toi A, Lawrentschuk N, Van der Kwast TH, Zlotta A, Kulkarni G, Hamilton R, Trachtenberg J, Evans A, Timilshina N, Fleshner NE, Finelli A.

Urology. 2013 Aug;82(2):405-9. doi: 10.1016/j.urology.2013.03.057. Epub 2013 Jun 2.

PMID:
23735610
41.

A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.

Wong LM, Alibhai SM, Trottier G, Timilshina N, Van der Kwast T, Zlotta A, Lawrentschuk N, Kulkarni G, Hamilton R, Ferrara S, Margel D, Trachtenberg J, Jewett MA, Toi A, Evans A, Fleshner NE, Finelli A.

Eur Urol. 2014 Sep;66(3):406-13. doi: 10.1016/j.eururo.2013.04.038. Epub 2013 May 2.

PMID:
23664820
42.

[A comparison of absorbed doses to water in photon beams in Japan Society of Medical Physics 01 and 12].

Kinoshita N, Takemura A, Nishimoto Y, Kita A, Toi A, Murai E, Shimada M, Sasamoto K, Adachi T.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2013 Mar;69(3):284-7. Japanese.

43.

[Usefulness of top-hat transform processing in whole body bone scintigraphy].

Kita A, Sugimoto K, Tsuchida T, Kishimoto T, Toi A, Shimada M, Adachi T.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2013 Jan;69(1):41-8. Japanese.

44.

ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan.

Salomon LJ, Alfirevic Z, Bilardo CM, Chalouhi GE, Ghi T, Kagan KO, Lau TK, Papageorghiou AT, Raine-Fenning NJ, Stirnemann J, Suresh S, Tabor A, Timor-Tritsch IE, Toi A, Yeo G.

Ultrasound Obstet Gynecol. 2013 Jan;41(1):102-13. doi: 10.1002/uog.12342. No abstract available. Erratum in: Ultrasound Obstet Gynecol. 2013 Feb;41(2):240.

45.

Role of transrectal ultrasonography in prostate cancer.

Ghai S, Toi A.

Radiol Clin North Am. 2012 Nov;50(6):1061-73. doi: 10.1016/j.rcl.2012.08.007. Review.

PMID:
23122038
47.

Exencephaly: a first-trimester diagnosis.

Johnson S, Toi A, Glanc P.

Ultrasound Q. 2012 Sep;28(3):209-11. doi: 10.1097/RUQ.0b013e3182635854. No abstract available.

PMID:
22902849
48.

Results of a surgically derived nomogram to predict Gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy.

Bowes D, Crook JM, Wallace K, Evans A, Toi A, Finelli A, Jewett MA, Fleshner N, Catton C.

Urology. 2012 Sep;80(3):649-55. doi: 10.1016/j.urology.2012.03.051. Epub 2012 Jun 13.

PMID:
22698474
49.

Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer.

Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R.

Clin Cancer Res. 2012 Apr 1;18(7):2108-14. doi: 10.1158/1078-0432.CCR-11-2711. Epub 2012 Mar 31.

50.

A simplified method to generate serotonergic neurons from mouse embryonic stem and induced pluripotent stem cells.

Shimada T, Takai Y, Shinohara K, Yamasaki A, Tominaga-Yoshino K, Ogura A, Toi A, Asano K, Shintani N, Hayata-Takano A, Baba A, Hashimoto H.

J Neurochem. 2012 Jul;122(1):81-93. doi: 10.1111/j.1471-4159.2012.07724.x. Epub 2012 Apr 4.

Supplemental Content

Support Center